Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business UpdateGlobeNewsWire • 11/28/23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business UpdateGlobeNewsWire • 11/28/23
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ETGlobeNewsWire • 11/21/23
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)GlobeNewsWire • 11/14/23
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)GlobeNewsWire • 11/14/23
STADA and Alvotech receive positive CHMP opinion for Europe's first ustekinumab biosimilar to StelaraGlobeNewsWire • 11/10/23
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04GlobeNewsWire • 10/12/23
Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq IcelandGlobeNewsWire • 10/05/23
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)Business Wire • 10/03/23
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)GlobeNewsWire • 10/03/23
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®GlobeNewsWire • 09/25/23
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)GlobeNewsWire • 09/20/23
Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewsWire • 09/11/23
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business UpdateGlobeNewsWire • 08/30/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the FirmAccesswire • 08/25/23
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ETGlobeNewsWire • 08/22/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 08/03/23
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/31/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the FirmAccesswire • 07/25/23